Controversies in the Management of Patent Ductus Arteriosus in Preterm InfantsNeha Chaudhary, Panayot Filipov, Alok Bhutada and Shantanu Rastogi*
Division of Neonatology, Department of Pediatrics, Maimonides Medical Center, Brooklyn NY, USA
- *Corresponding Author:
- Shantanu Rastogi
Albert Einstein College of Medicine
Maimonides Infant and Children’s Hospital
Brooklyn NY, USA
E-mail: [email protected]
Received date: October 17, 2016; Accepted date: November 07, 2016; Published date: November 17, 2016
Citation: Chaudhary N, Filipov P, Bhutada A, Rastogi S (2016) Controversies in the Management of Patent Ductus Arteriosus in Preterm Infants. J Neonatal Biol 5:238. doi:10.4172/2167-0897.1000238
Copyright: © 2016 Chaudhary N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Patent Ductus Arteriosus (PDA) is present in 40-60 percent of preterm infants with its incidence inversely proportional to the gestational age. Management of PDA in extreme prematurity and extremely low birth weight infants is controversial specially with newer literature showing no significant benefits in long term outcomes in infants who were treated as compared to those who were not treated. Further the mortality and morbidities in preterm infants may not be entirely related to PDA as previously ascribed. Hence there is controversy as to which preterm infants benefit from treatment, when should they be treated and which treatment modalities should be used. We have reviewed the current literature to bring out the controversies in the answer to these questions.